Open AccessThe use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab
Author(s) -
Philip Friedlander
Publication year - 2019
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm.2019.01.74
Subject(s) - pembrolizumab , medicine , oncology , melanoma , stage (stratigraphy) , baseline (sea) , overall survival , immunotherapy , cancer research , cancer , biology , paleontology , fishery